© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Biosimilars
Review Paper Argues for Broader Use of Riabni, a Rituxan Biosimilar
June 03, 2022
The review, partly funded by Amgen, the maker of Riabni, makes the case for using the biosimilar to Rituxan for all indications of the originator.
Preventive Care, Biosimilars Can Ease Costs of Treating Neutropenia
June 02, 2022
The average sales price (ASP) for biosimilars of Neupogen has declined more than 50% since these lower cost agents began to be sold in 2015.
Biosimilars Can Help Lower Patient Drug Costs When the Right Teams Come Together: Prime Therapeutics Executive
May 29, 2022
Pharmacy benefit managers can help health plans understand when to best leverage and align to biosimilars and other cost-effective treatments, argues Prime Therapeutics' Kelly McGrail-Pokuta.
Humira, the biosimilars are coming, the biosimilars are coming!
May 19, 2022
Circle 2023 on your calendar. That's when as many as 11 biosimilars to Humira are headed for the U.S. market.
Efforts are Needed from Payers for Improvements in Biosimilars
May 12, 2022
Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.
“Patent Thickets” on Biologics and What Could Be Done To Chop Them Down to Size
May 10, 2022
Multiple patents on original biologics delay when biosimilars get on the market in the US. University of Denver Sturm College of Law legal experts argue in a preprint that changes in how the original patents are written could reduce the number of duplicative patents and legal gamesmanship.
Will Cyltezo Be Accepted As Interchangeabe With Humira? Researchers Sow Some Doubt.
May 10, 2022
A Cleveland Clinic researcher anticipates that the FDA’s definition of strength of formulation could impair acceptance of Boehringer Ingelheim’s biosimilar to Humira (adalimumab), even though the FDA has approved the biosimilar as “interchangeable” to Humira.
Biosimilars Made a Significant Dent on 2021 Drug Spending
May 09, 2022
Although spending on prescription drugs marched higher in 2021, the spending might have been significantly higher were it not for the savings from biosimilars, which appear to be gaining traction, according to a new report.
Humira Biosimilars Are Hitting the Market in 2023. Finally. But Will Prescriptions Follow?
April 07, 2022
Marcus Snow, MD, , chair of the American College of Rheumatology’s Committee on Rheumatologic Care, discusses how additional clinical data and interchangeability designations could help build momentum for use of Humira (adalimumab) biosimilars when they start to arrive in 2023.
Research Examines Self-administered Humira Biosimilars
April 07, 2022
In a pair of recent studies, investigators evaluated biosimilar forms of Humira (adalimumab) in prefilled syringes, prefilled pens, and autoinjector devices.